Top

American Journal of Clinical Dermatology

Published in:

01-06-2013 | Evidence-Based Review Article

The Effect of Folate Supplementation on Methotrexate Efficacy and Toxicity in Psoriasis Patients and Folic Acid Use by Dermatologists in the USA

Authors: Amir Al-Dabagh, Scott A. Davis, Megan A. Kinney, Karen Huang, Steven R. Feldman

Published in: American Journal of Clinical Dermatology | Issue 3/2013

Abstract

Background

Methotrexate (MTX) is an effective treatment for psoriasis but its use is limited by its toxicity. Folate supplementation can be used to reduce the adverse effects of MTX, though this may impact efficacy. The frequency of folic acid supplementation is not well characterized.

Purpose

The objective of this study was to review the literature involving the use of folate in patients (in particular those with psoriasis) treated with MTX and analyze trends in folic acid use.

Methods

We searched PubMed from 1 May 1989 through 1 April 2012 using the terms ‘folic acid,’ ‘folinic acid,’ ‘folate,’ ‘supplementation,’ and ‘methotrexate.’ We also used the National Ambulatory Medical Care Survey (NAMCS) database to collect data regarding trends in MTX use and folic acid supplementation by physicians in the USA from 1993 through 2009. We assessed data including the number of MTX visits, rate of folic acid use, diagnoses, physician specialty, and demographics of patients. We used linear regression to analyze the change in folic acid use over time.

Results

Twenty-six published trials were included addressing folic acid supplementation with MTX. The majority found a benefit to folic acid supplementation, but there were only seven studies in psoriasis. Dermatologists were among the highest prescribers of MTX, and psoriasis was commonly treated with MTX. Folic acid supplementation significantly increased over this time period (p < 0.0001). However, dermatologists ranked lowest for their folate use, co-prescribing folate to only 9.1 % of MTX-treated patients.

Limitations

In contrast to rheumatoid arthritis, there is a scarcity of literature describing the effect of folate on MTX toxicity and efficacy in psoriasis patients. NAMCS data only included outpatient visits to non-federally employed physicians, and there is the possibility of healthcare providers not documenting over-the-counter folic acid usage. Lastly, doses of MTX and folic acid were not recorded in the database.

Conclusion

Dermatologists were the least likely specialists to supplement MTX with folic acid. The evidence for supplementation of folic acid is mixed. The literature confirms a reduction in the adverse effects of MTX but less strongly that there may be a reduction in efficacy too. Keeping in mind the potential for folate to reduce MTX efficacy, folic acid supplementation should be considered in MTX-treated patients.

Morgan S, Alarcon GS, Krumdieck CL. Folic acid supplementation during methotrexate therapy: it makes sense. J Rheumatol. 1993;20(6):929–30.PubMed

Morgan SL, Oster RA, Lee JY, et al. The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. Arthritis Rheum. 2004;50(10):3104–11.PubMedCrossRef

Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1990;33(1):9–18.PubMedCrossRef

Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med. 1994;121(11):833–41.PubMedCrossRef

Morgan SL, Baggott JE, Lee JY, et al. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol. 1998;25(3):441–6.PubMed

Masuria BL, Mittal A, Gupta LK, et al. Methotrexate: side effects and the role of folic acid supplementation in psoriasis: a study. Indian J Dermatol Venereol Leprol. 1997;63(4):219–22.PubMed

Huemer M, Fodinger M, Huemer C, et al. Hyperhomocysteinemia in children with juvenile idiopathic arthritis is not influenced by methotrexate treatment and folic acid supplementation: a pilot study. Clin Exp Rheumatol. 2003;21(2):249–55.PubMed

Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol. 2005;53(4):652–9.PubMedCrossRef

Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451–85.PubMedCrossRef

10.

van Ede AE, Laan RF, Blom HJ, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford). 2002;41(6):658–65.CrossRef

11.

Hornung N, Ellingsen T, Stengaard-Pedersen K, et al. Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement. J Rheumatol. 2004;31(12):2374–81.PubMed

12.

Chladek J, Simkova M, Vaneckova J, et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission–induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol. 2008;64(4):347–55.PubMedCrossRef

13.

Clare G, Colley S, Kennett R, et al. Reversible optic neuropathy associated with low-dose methotrexate therapy. J Neuroophthalmol. 2005;25(2):109–12.PubMedCrossRef

14.

Len C, Hilario MO, Kawakami E, et al. Gastroduodenal lesions in children with juvenile rheumatoid arthritis. Hepatogastroenterology. 1999;46(26):991–6.PubMed

15.

Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br J Dermatol. 2009;160(3):622–8.PubMedCrossRef

16.

Guzzo C. Folic acid supplementation with methotrexate therapy: what benefit if any? J Am Acad Dermatol. 1994;31(4):689.PubMedCrossRef

17.

Shiroky JB. The use of folates concomitantly with low-dose pulse methotrexate. Rheum Dis Clin North Am. 1997;23(4):969–80.PubMedCrossRef

18.

Gisondi P, Fantuzzi F, Malerba M, et al. Folic acid in general medicine and dermatology. J Dermatolog Treat. 2007;18(3):138–46.PubMedCrossRef

19.

Hughes R, Harries M, Chalmers RJ, et al. Folic acid supplementation and methotrexate therapy for psoriasis. J Am Acad Dermatol. 2006;55(2):366–7.PubMedCrossRef

20.

Hoekstra M, van de Laar MA, Bernelot Moens HJ, et al. Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis. J Rheumatol. 2003;30(11):2325–9.PubMed

21.

Hoekstra M, van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62(5):423–6.PubMedCrossRef

22.

Niehues T, Horneff G, Michels H, et al. Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria. Rheumatol Int. 2005;25(3):169–78.PubMedCrossRef

23.

Strand V, Morgan SL, Baggott JE, et al. Folic acid supplementation and methotrexate efficacy: comment on articles by Schiff, Emery et al, and others. Arthritis Rheum. 2000;43(11):2615–6.PubMedCrossRef

24.

Bressolle F, Kinowski JM, Morel J, et al. Folic acid alters methotrexate availability in patients with rheumatoid arthritis. J Rheumatol. 2000;27(9):2110–4.PubMed

25.

Franks P, Clancy CM, Nutting PA. Defining primary care: empirical analysis of the National Ambulatory Medical Care Survey. Med Care. 1997;35(7):655–68.PubMedCrossRef

26.

Binns HJ, Lanier D, Pace WD, et al. Describing primary care encounters: the Primary Care Network Survey and the National Ambulatory Medical Care Survey. Ann Fam Med. 2007;5(1):39–47.PubMedCrossRef

27.

Kirby B, Lyon CC, Griffiths CE, et al. The use of folic acid supplementation in psoriasis patients receiving methotrexate: a survey in the United Kingdom. Clin Exp Dermatol. 2000;25(4):265–8.PubMedCrossRef

28.

Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol. 1993;28(3):466–9.PubMedCrossRef

29.

Griffith SM, Fisher J, Clarke S, et al. Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? Rheumatology (Oxford). 2000;39(10):1102–9.

30.

Salim A, Tan E, Ilchyshyn A, et al. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2006;154(6):1169–74.PubMedCrossRef

31.

Roenigk HH Jr, Fowler-Bergfeld W, Curtis GH. Methotrexate for psoriasis in weekly oral doses. Arch Dermatol. 1969;99(1):86–93.PubMedCrossRef

32.

Ive FA, De Saram CF. Methotrexate and the citrovorum factor in the treatment of psoriasis. Trans St Johns Hosp Dermatol Soc. 1970;56(1):45–7.PubMed

33.

Hills RJ, Ive FA. Folinic acid rescue used routinely in psoriatic patients with known methotrexate “sensitivity”. Acta Derm Venereol. 1992;72(6):438–40.PubMed

34.

Campalani E, Arenas M, Marinaki AM, et al. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol. 2007;127(8):1860–7.PubMedCrossRef

35.

Leeb BF, Witzmann G, Ogris E, et al. Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. Clin Exp Rheumatol. 1995;13(4):459–63.PubMed

36.

Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20(3 Suppl.):21–35.PubMedCrossRef

37.

Ortiz Z, Shea B, Suarez-Almazor ME, et al. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis: a metaanalysis of randomized controlled trials. J Rheumatol. 1998;25(1):36–43.PubMed

38.

Visser K, van der Heijde DM. Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature. Clin Exp Rheumatol. 2009;27(6):1017–25.PubMed

Title: The Effect of Folate Supplementation on Methotrexate Efficacy and Toxicity in Psoriasis Patients and Folic Acid Use by Dermatologists in the USA
Authors: Amir Al-Dabagh
Scott A. Davis
Megan A. Kinney
Karen Huang
Steven R. Feldman
Publication date: 01-06-2013
Publisher: Springer International Publishing AG
Published in: American Journal of Clinical Dermatology / Issue 3/2013
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-013-0017-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Effect of Folate Supplementation on Methotrexate Efficacy and Toxicity in Psoriasis Patients and Folic Acid Use by Dermatologists in the USA

Abstract

Background

Purpose

Methods

Results

Limitations

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Purpose

Methods

Results

Limitations

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2013

Medication Adherence, Healthcare Costs and Utilization Associated with Acne Drugs in Medicaid Enrollees with Acne Vulgaris

Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions

Pulsed Dye Laser in the Treatment of Localized Scleroderma and Its Effects on CD34+ and Factor XIIIa+ Cells: An Immunohistochemical Study

Diagnosis and Treatment of Pediatric Psoriasis: Current and Future

Etiology and Therapeutic Management of Erythema Nodosum During Pregnancy: An Update

Penicillamine Revisited: Historic Overview and Review of the Clinical Uses and Cutaneous Adverse Effects